Spectranetics releases new lead locking device

Spectranetics has released its LLD EZ lead locking device (LLD) for the removal of non-functional or infected pacing and defibrillation leads, which allows physicians to secure the entire lead creating traction to enable the removal process.

The company said its LLD EZ provides a flexible solution to address the removal of leads from scar tissue holding them in place. LLD EZ employs a braided mesh that expands to secure leads along their hollow inner lumen permitting physicians to apply steady traction on the lead. The locking mechanism can be reversed, or unlocked, if the physician needs to remove the device from the lead or reposition it, according to the Colorado Springs, Colo.-based Spectranetics.

“Controlling the entire lead length throughout the removal process is important for achieving safe and complete removal,” said Laurence Epstein, MD, chief of cardiac arrhythmia services at Brigham and Women’s Hospital in Boston.

LLD EZ also features an enhanced tip design and sleek profile to facilitate tracking and passage of the device through tight curves and beyond lumen damage, the company said.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.